RCJ-41T Cell Line

Overview

This tumor cell line is cultured from patient tumor tissue; cells were passaged 30 times to confirm immortalization. Cell characterization was conducted through STR of the patient tumor and cell line.

Key elements and design rationale

• Model identity: RCJ-41T Cell Line is supplied as a tumor cell line derived from Human kidney.
• Growth properties: Adherent, epithelial
• Growth conditions: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. PriGrow II (TM002) + 5% FBS + 1% NEAA (TM068) + 1 mM Sodium Pyruvate (TM057) + 10 mM HEPES (TM058) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. Cells are sensitive to freeze/thaw cycles; supplementing media with 20% FBS is recommended during the initial thaw. Once cells recover, 5% FBS is sufficient.
• Product format: Frozen, BSL-2

This cell-based model is generally used in cancer biology, phenotype comparison, and response profiling studies. Donor/background information is available for contextual interpretation.

Biological background

RCJ-41T (T8112) and RCJ-41T2 (T8113) are tumor-derived cell lines originating from the same donor and tissue source, diagnosed with sarcomatoid chromophobe renal cell carcinoma (RCC). These lines represent distinct isolates from the same primary tumor, potentially capturing clonal or regional heterogeneity. RCJ-41M (T8114), derived from a metastatic lesion in the same patient, offers a matched model for comparing primary versus metastatic tumor behavior within a consistent genetic background. Donor/background information provided for this product: Female, 37, Sarcomatoid.

Research relevance and current trends

• Cell-line models continue to be used for tumor phenotype comparison, pathway perturbation studies, and assay development in controlled in vitro systems.
• Engineered and subtype-defined tumor lines are often used to compare growth behavior, reporter output, and response patterns across matched experimental conditions.
• When metastatic or lineage features are described, investigators commonly interpret results alongside morphology, passage history, and culture environment.

Common research applications

• Cancer biology studies that compare proliferation-associated behavior, morphology, and pathway responses in vitro.
• Assay development for treatment response, reporter monitoring, or phenotype comparison under matched culture conditions.
• Side-by-side comparison of engineered versus parental background characteristics when relevant to the study design.

Changes in morphology, growth rate, viability, or reporter signal are typically interpreted together with passage history, culture matrix, and the specified growth conditions for the model.

Notes for experimental interpretation

• Morphology, doubling behavior, and reporter or marker output can shift with passage number, substrate choice, and medium composition; these variables should be recorded alongside experimental readouts.
• Matched controls such as parental cells, untreated cultures, or parallel cultures maintained under identical conditions help distinguish background effects from biology of interest.

Culture and product details

• Growth Conditions: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. PriGrow II (TM002) + 5% FBS + 1% NEAA (TM068) + 1 mM Sodium Pyruvate (TM057) + 10 mM HEPES (TM058) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. Cells are sensitive to freeze/thaw cycles; supplementing media with 20% FBS is recommended during the initial thaw. Once cells recover, 5% FBS is sufficient.
• 3D Culture Conditions: Procedure Preparation (before 3D Culture): Thaw cells following "Thawing Protocol" and "Growth Conditions". Expand cells for one passage, then seed for spheroid generation (3D culture). Subculture Protocol: Aspirate the supernatant and wash cells with 1X PBS (pH 7.4) (G5000). Dissociate cells using 1–1.5 ml of Gentle Dissociation Solution (TM080). Observe the cells under a microscope to confirm detachment (typically within 2–10 minutes). Cells that are difficult to detach can be put in 37 °C for several minutes to facilitate detachment. Neutralize using an equal volume of complete growth media (must contain serum) or using Trypsin Neutralizing Solution (TM069). Transfer culture suspension into sterile conical centrifuge tube (G5500), and centrifuge at 125 x g for 5 minutes. The actual centrifuge duration and speed may vary depending on the cell type. Aspirate supernatant and re-suspend the pellet with pre-warmed fresh complete growth media for 3D Culture. Spheroid Generation Protocol: Count cells and viability using cell counter or hemocytometer with Trypan Blue Stain (TM071). Proceed if cells are >90% viability. Seed 500 to 10,000 cells per well in SpheroWell™ 96 Well Plate (G7540), final volume maintained at 100 μl per well. Avoid cell clumps (clumps will not generate uniform spheroids). Count as Day 0. Tip: Fill the outermost wells of the plate with 1X PBS (pH 7.4) (G5000) to prevent evaporation of media during incubation. (Recommended) Centrifuge the sealed plate at 300 x g for 5 minutes. Place in the incubator set at 37 °C, 5% CO₂. Change Media: Every 2–3 days, add 100 μl of fresh media slowly along the wall of the well to avoid disrupting spheroids at the bottom. Take out 100 μl of media slowly and discard from the well. (Recommended, but optional) Centrifuge the sealed plate at 300 x g for 5 minutes. Monitor the Cells for 3D/Spheroid Formation: Spheroid formation will appear between day 5 and 10.

Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.